Furthermore, in vitro inhibition of Stat3 activation in glioblastoma resulted in a decrease in the proliferative capacity and an increase in cellular sensitivity to TMZ treatment [10, 15, 16]. The gene discussed is STAT3; the disease is glioblastoma.